GlaxoSmithKline Pharmaceuticals is the Indian arm of GSK, making branded and over-the-counter medicines such as Crocin, Calpol and Horlicks-linked nutrition products, plus prescription drugs sold through its domestic branded generics franchise. Its edge is a long-established brand portfolio with strong consumer recognition and pricing power, reflected in a 64.2% gross margin and a 29.8% operating margin. Revenue growth of 16.6% gives it a fast-growing top line for a company of its scale, and the forward P/E of 30.7 against a trailing 38.6 implies the market expects earnings to rise sharply over the next year. At 412.3B INR in market capitalisation with no index membership, it is a mid-to-large name that is easy to overlook, which may make the premium valuation and the earnings step-up worth a closer look.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:52 CEST | ACCE price target | ₹2380 | first publication | ₹2434 |
Answered from GlaxoSmithKline Pharmaceuticals Limited fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| GLAXO.NS GlaxoSmithKline Pharmaceuticals Limited | ₹2404.70 | - | - | 38.1x | - | 100 | 62 |
| OGN Organon & Co. Common Stock | $13.75 | $7 | 111% above | 17.6x | 24.0% | 60 | 64 |
| GRFS Grifols S.A. American Depositary Shares | $7.56 | $10 | 25% below | 9.9x | 6.9% | 53 | 57 |
| 4536.T Santen Pharmaceutical Co., Ltd. | ¥1734.00 | - | - | 14.6x | 13.4% | 69 | 61 |
| VIRP.PA Virbac SA | €349.00 | €345 | 1% above | 18.8x | 13.6% | 80 | 60 |
| 4528.T Ono Pharmaceutical Co., Ltd. | ¥2499.00 | - | - | 15.4x | 9.3% | 82 | 73 |
| GRF.MC Grifols | €10.17 | €8 | 26% above | 15.4x | 6.9% | 53 | 64 |
Where GLAXO.NS ranks against its sector peers on each metric.